One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus
暂无分享,去创建一个
P. Jahrling | M. Frieman | L. Hensley | C. Wirblich | J. Bernbaum | M. Schnell | Drishya Kurup | Reed F. Johnson | C. Coleman | Tara S. Abraham
[1] I. Sola,et al. Molecular Basis of Coronavirus Virulence and Vaccine Development , 2016, Advances in Virus Research.
[2] M. Yahia. Saudi Arabia , 2016, Nature.
[3] K. Modjarrad. MERS-CoV vaccine candidates in development: The current landscape , 2016, Vaccine.
[4] H. Feldmann,et al. A Comparative Review of Animal Models of Middle East Respiratory Syndrome Coronavirus Infection , 2016, Veterinary pathology.
[5] D. Swerdlow,et al. Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014 , 2016, The American Journal of Pathology.
[6] S. Perlman,et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus , 2015, Cellular and Molecular Immunology.
[7] Lloyd H. Michael,et al. The Guide for the Care and Use of Laboratory Animals. , 2016, ILAR journal.
[8] P. Jahrling,et al. Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses. , 2015, The Journal of infectious diseases.
[9] S. Yerly,et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. , 2015, The Lancet. Infectious diseases.
[10] S. Perlman,et al. Identification of the Mechanisms Causing Reversion to Virulence in an Attenuated SARS-CoV for the Design of a Genetically Stable Vaccine , 2015, PLoS pathogens.
[11] Shibo Jiang,et al. Middle East respiratory syndrome: current status and future prospects for vaccine development , 2015, Expert opinion on biological therapy.
[12] N. Sardesai,et al. A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates , 2015, Science Translational Medicine.
[13] Ulas Bagci,et al. Evaluation of candidate vaccine approaches for MERS-CoV , 2015, Nature Communications.
[14] Y. Guan,et al. Emerging Problems in Infectious Diseases Lessons to learn from MERS-CoV outbreak in South Korea , 2015 .
[15] G. Yancopoulos,et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection , 2015, Proceedings of the National Academy of Sciences.
[16] S. Yi,et al. Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[17] G. Sutter,et al. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein , 2015, Journal of Virology.
[18] M. Frieman,et al. Growth and Quantification of MERS‐CoV Infection , 2015, Current protocols in toxicology / editorial board, Mahin D. Maines (editor-in-chief) ... [et al.].
[19] R. Cattaneo,et al. Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics. , 2015, Virology.
[20] W. Tan,et al. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus , 2015, Immunology.
[21] Yang Yang,et al. The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. , 2014, Viral immunology.
[22] L. Pelkmans,et al. Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway in a Proteolysis-Dependent Manner , 2014, PLoS pathogens.
[23] L. Madoff,et al. Health-care associate transmission of Middle East Respiratory Syndrome Corona virus, MERS-CoV, in the Kingdom of Saudi Arabia , 2014, International Journal of Infectious Diseases.
[24] H. Feldmann,et al. Rhabdovirus-Based Vaccine Platforms against Henipaviruses , 2014, Journal of Virology.
[25] Christian Drosten,et al. Evidence for camel-to-human transmission of MERS coronavirus. , 2014, The New England journal of medicine.
[26] M. Schnell,et al. Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo , 2014, Molecular therapy. Methods & clinical development.
[27] Shibo Jiang,et al. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design , 2014, Vaccine.
[28] A. Gambotto,et al. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice , 2014, Vaccine.
[29] M. Frieman,et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice , 2014, Vaccine.
[30] Z. Memish. MERS-COV , 2014, International Journal of Infectious Diseases.
[31] R. Baric,et al. Rapid generation of a mouse model for Middle East respiratory syndrome , 2014, Proceedings of the National Academy of Sciences.
[32] Shibo Jiang,et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines , 2014, Vaccine.
[33] Krystal L. Matthews,et al. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. , 2014, The Journal of general virology.
[34] C. Wirblich,et al. Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: implication for post-exposure treatment. , 2013, Vaccine.
[35] Zhaohui Qian,et al. Role of the Spike Glycoprotein of Human Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Virus Entry and Syncytia Formation , 2013, PloS one.
[36] Michael G. Katze,et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques , 2013, Proceedings of the National Academy of Sciences.
[37] I. Sola,et al. Engineering a Replication-Competent, Propagation-Defective Middle East Respiratory Syndrome Coronavirus as a Vaccine Candidate , 2013, mBio.
[38] M. Katze,et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques , 2013, Nature Medicine.
[39] M. Frieman,et al. Emergence of the Middle East Respiratory Syndrome Coronavirus , 2013, PLoS pathogens.
[40] Z. Memish,et al. Middle East respiratory syndrome coronavirus infections in health care workers. , 2013, The New England journal of medicine.
[41] A. Debnath,et al. Identification of a Receptor-Binding Domain in the S Protein of the Novel Human Coronavirus Middle East Respiratory Syndrome Coronavirus as an Essential Target for Vaccine Development , 2013, Journal of Virology.
[42] S Cauchemez,et al. Transmission scenarios for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and how to tell them apart. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[43] H. Feldmann,et al. Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine , 2013, PLoS pathogens.
[44] H. Feldmann,et al. Pneumonia from human coronavirus in a macaque model. , 2013, The New England journal of medicine.
[45] S. Perlman,et al. Complete Protection against Severe Acute Respiratory Syndrome Coronavirus-Mediated Lethal Respiratory Disease in Aged Mice by Immunization with a Mouse-Adapted Virus Lacking E Protein , 2013, Journal of Virology.
[46] Christian Drosten,et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.
[47] F. Cliquet,et al. Evaluation of an ELISA to detect rabies antibodies in orally vaccinated foxes and raccoon dogs sampled in the field. , 2013, Journal of virological methods.
[48] WHO Statement on the third meeting of the IHR Emergency committee concerning Middle East respiratory syndrome coronavirus (MERS-CoV). , 2013, Releve epidemiologique hebdomadaire.
[49] P. Jahrling,et al. A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence. , 2012, Virology.
[50] A. Osterhaus,et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.
[51] P. Jahrling,et al. Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. , 2012, Vaccine.
[52] Kevin W Eliceiri,et al. NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.
[53] F. Cliquet,et al. Evaluation of ELISA for detection of rabies antibodies in domestic carnivores. , 2012, Journal of virological methods.
[54] P. Jahrling,et al. Inactivated or Live-Attenuated Bivalent Vaccines That Confer Protection against Rabies and Ebola Viruses , 2011, Journal of Virology.
[55] C. Schwegmann-Wessels,et al. The Spike Protein of Infectious Bronchitis Virus Is Retained Intracellularly by a Tyrosine Motif , 2007, Journal of Virology.
[56] F. Boué,et al. A quantitative indirect ELISA to monitor the effectiveness of rabies vaccination in domestic and wild carnivores. , 2007, Journal of immunological methods.
[57] R. Pomerantz,et al. Rabies virus glycoprotein as a carrier for anthrax protective antigen , 2006, Virology.
[58] G. Herrler,et al. Intracellular Transport of the S Proteins of Coronaviruses , 2006, Advances in experimental medicine and biology.
[59] L. Enjuanes,et al. A Novel Sorting Signal for Intracellular Localization Is Present in the S Protein of a Porcine Coronavirus but Absent from Severe Acute Respiratory Syndrome-associated Coronavirus , 2004, Journal of Biological Chemistry.
[60] M. Aubert,et al. Elimination of terrestrial rabies in Western European countries. , 2004, Developments in biologicals.
[61] R. Pomerantz,et al. Covalently Linked Human Immunodeficiency Virus Type 1 gp120/gp41 Is Stably Anchored in Rhabdovirus Particles and Exposes Critical Neutralizing Epitopes , 2003, Journal of Virology.
[62] J. Orenstein,et al. Functional Human Immunodeficiency Virus Type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and Env Expressed from a Single Rhabdovirus-Based Vaccine Vector Genome , 2003, Journal of Virology.
[63] R. Pomerantz,et al. Second-Generation Rabies Virus-Based Vaccine Vectors Expressing Human Immunodeficiency Virus Type 1 Gag Have Greatly Reduced Pathogenicity but Are Highly Immunogenic , 2003, Journal of Virology.
[64] J. Dubuisson,et al. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. , 2002, Virology.
[65] R. Pomerantz,et al. Recombinant rabies virus as potential live-viral vaccines for HIV-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[66] K. Conzelmann,et al. Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19. , 1990, Virology.